TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Moderna Lead
Play
INVESTING

10 Best Stocks in the Nasdaq This Past Week: Moderna Climbs

PRESS RELEASES

Vertex Announces FDA Clearance Of Investigational New Drug (IND) Application For VX-880, A Novel Cell Therapy For The Treatment Of Type 1 Diabetes (T1D)

PRESS RELEASES

Vertex Announces U.S. FDA Acceptance Of Supplemental New Drug Application For TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations

PRESS RELEASES

Vertex To Announce Fourth-Quarter 2020 Financial Results On February 1

PRESS RELEASES

Vertex To Present At The J.P. Morgan Healthcare Conference On January 11

PRESS RELEASES

Vertex Announces New Drug Submission For Investigational Triple Combination Medicine For The Treatment Of Cystic Fibrosis Has Been Accepted For Priority Review By Health Canada

PRESS RELEASES

Skyhawk And Vertex Establish A Strategic Collaboration To Discover And Develop Novel Small Molecules That Modulate RNA Splicing For Serious Diseases

PRESS RELEASES

Vertex Announces FDA Approvals Of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor And Ivacaftor), SYMDEKO® (tezacaftor/ivacaftor And Ivacaftor) And KALYDECO® (ivacaftor) For Use In People With CF With Certain Rare Mutations

Moderna Lead
INVESTING

10 Best Stocks in the Nasdaq This Past Week: Moderna Climbs

PRESS RELEASES

Vertex Announces European Commission Approval For SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) For Eligible Children With Cystic Fibrosis Ages 6-11 Years

PRESS RELEASES

Vertex Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Investment Corporation

PRESS RELEASES

Vertex To Present At The Jefferies Virtual London Health Care Conference On November 19

PRESS RELEASES

Vertex Announces European Commission Approval For KALYDECO® (ivacaftor) As First And Only CFTR Modulator To Treat Eligible Infants With Cystic Fibrosis As Early As Four Months Of Age

Vertex Pharma (VRTX) Stock Lower on Q3 Miss
INVESTING

Vertex Pharma Off After Analysts Comment on Drug-Trial Halt

PRESS RELEASES

Vertex Provides Update On Its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency

PRESS RELEASES

FDA Approves KALYDECO® (ivacaftor) As First And Only CFTR Modulator To Treat Eligible Infants With CF As Early As Four Months Of Age

PRESS RELEASES

Moderna And Vertex Establish New Collaboration To Treat Cystic Fibrosis Using Gene Editing

PRESS RELEASES

FDA Accepts Vertex's Supplemental New Drug Applications For TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor And Ivacaftor), SYMDEKO® (tezacaftor/ivacaftor And Ivacaftor) And KALYDECO® (ivacaftor) For Additional CFTR Mutations

PRESS RELEASES

European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) In Combination With Ivacaftor To Treat Cystic Fibrosis In People Ages 12 Years And Older

Jim Cramer to Interview T-Mobile CEO John Legere on 'Mad Money'
JIM CRAMER

Small Biz Woes: Cramer's 'Mad Money' Recap (Monday 8/17/20)

Midday Report: Advance Auto Parts Drags on S&P 500; Wall Street Rally Stalls
JIM CRAMER

Headlight Stocks: Cramer's 'Mad Money' Recap (Wednesday 8/5/20)

PRESS RELEASES

Vertex Pharmaceuticals Selects TRIA To Design Laboratory And Office For New 268,000 SF VCGT Research Site

PRESS RELEASES

Vertex To Announce Second-Quarter 2020 Financial Results On July 30

PRESS RELEASES

Vertex Announces Expansion Of Reimbursement Agreement With NHS England To Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) In Combination With KALYDECO® (ivacaftor)

PRESS RELEASES

Vertex And The Vertex Foundation Commit $4 Million To Support Racial Equity And Social Justice